INVESTOR RELATIONS

News

Date Title and Summary Additional Formats
Toggle Summary NantKwest Announces Presentation of Preclinical Data of HER2.taNK at the San Antonio Breast Cancer Symposium (SABCS)
“Novel protocol combining metronomic Nant-paclitaxel with HER2-targeted natural killer cells (innate immunotherapy) for HER2-positive metastatic breast cancer” CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 9, 2015-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage
View HTML
Toggle Summary NantKwest Announces Presentation at the American Society of Hematology (ASH) Annual Meeting; NK-92 Phase 1 Clinical Data on Dosing and Long-Term Survival in Relapsed Hematological Malignancies
CULVER CITY, Calif. --(BUSINESS WIRE)--Dec. 3, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced that
View HTML
Toggle Summary NantKwest Names Angela Wilson Chief Financial Officer
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 17, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases, today announced the
View HTML
Toggle Summary NantKwest Announces $50 Million Stock Repurchase Program
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 12, 2015-- NantKwest Inc. (Nasdaq:NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of our immune system using natural killer (NK) cells to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest Announces Presentations at Upcoming Investment Conference Meetings
CULVER CITY, Calif. --(BUSINESS WIRE)--Nov. 2, 2015-- NantKwest Inc. (Nasdaq:NK) today announced that the company will be presenting at the following upcoming investment conferences in November and December: Citi 2015 Global Healthcare Conference, Jefferies 2015 Global Healthcare Conference and the
View HTML
Toggle Summary NantKwest Continues the Strengthening of Its Leadership Team and Appoints a Seasoned Bioprocessing Manufacturing Executive
Stephen Farrand , Ph.D., former Merck executive appointed Senior Vice President Global Manufacturing CULVER CITY, Calif. --(BUSINESS WIRE)--Oct. 6, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using
View HTML
Toggle Summary NantKwest Augments, Strengthens Senior Management Team
-- Company Adds Clinical Development , Medical Affairs and M&A Executives -- CULVER CITY, Calif. --(BUSINESS WIRE)--Sep. 22, 2015-- NantKwest, Inc. (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to
View HTML
Toggle Summary NantKwest Announces Prostate Cancer Foundation $1 Million Challenge Award to Study a Novel Natural Killer Cell Therapy in Prostate Cancer
LOS ANGELES --(BUSINESS WIRE)--Aug. 26, 2015-- NantKwest (Nasdaq:NK), working with Ganesh Palapattu, MD and his team at the University of Michigan , along with Karen Knudsen , PhD and her group at Thomas Jefferson University , announced a $1 Million Challenge award from the Prostate Cancer
View HTML
Toggle Summary NantKwest Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CULVER CITY, Calif. --(BUSINESS WIRE)--Jul. 31, 2015-- NantKwest, Inc. (formerly Conkwest, Inc. ) (Nasdaq: NK), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory
View HTML
Toggle Summary NantKwest Announces Pricing of Initial Public Offering
CULVER CITY, Calif.--( BUSINESS WIRE )--NantKwest, Inc. (formerly Conkwest, Inc.), a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, announced today the
View HTML